Literature DB >> 30100187

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Veronica Rodriguez-Bravo1, Raffaella Pippa2, Won-Min Song3, Marc Carceles-Cordon4, Ana Dominguez-Andres2, Naoto Fujiwara5, Jungreem Woo2, Anna P Koh5, Adam Ertel6, Ravi K Lokareddy7, Alvaro Cuesta-Dominguez8, Rosa S Kim5, Irene Rodriguez-Fernandez4, Peiyao Li9, Ronald Gordon4, Hadassa Hirschfield5, Josep M Prats10, E Premkumar Reddy11, Alessandro Fatatis12, Daniel P Petrylak13, Leonard Gomella14, W Kevin Kelly15, Scott W Lowe16, Karen E Knudsen15, Matthew D Galsky17, Gino Cingolani7, Amaia Lujambio8, Yujin Hoshida5, Josep Domingo-Domenech18.   

Abstract

Nuclear pore complexes (NPCs) regulate nuclear-cytoplasmic transport, transcription, and genome integrity in eukaryotic cells. However, their functional roles in cancer remain poorly understood. We interrogated the evolutionary transcriptomic landscape of NPC components, nucleoporins (Nups), from primary to advanced metastatic human prostate cancer (PC). Focused loss-of-function genetic screen of top-upregulated Nups in aggressive PC models identified POM121 as a key contributor to PC aggressiveness. Mechanistically, POM121 promoted PC progression by enhancing importin-dependent nuclear transport of key oncogenic (E2F1, MYC) and PC-specific (AR-GATA2) transcription factors, uncovering a pharmacologically targetable axis that, when inhibited, decreased tumor growth, restored standard therapy efficacy, and improved survival in patient-derived pre-clinical models. Our studies molecularly establish a role of NPCs in PC progression and give a rationale for NPC-regulated nuclear import targeting as a therapeutic strategy for lethal PC. These findings may have implications for understanding how NPC deregulation contributes to the pathogenesis of other tumor types.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E2F1; GATA2; MYC; POM121; androgen receptor; importin β; nuclear import; nuclear pore; nuclear transport; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30100187      PMCID: PMC6150493          DOI: 10.1016/j.cell.2018.07.015

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  70 in total

Review 1.  Nuclear pores as versatile platforms for gene regulation.

Authors:  Pau Pascual-Garcia; Maya Capelson
Journal:  Curr Opin Genet Dev       Date:  2014-03-12       Impact factor: 5.578

Review 2.  Gene regulation by nucleoporins and links to cancer.

Authors:  Alwin Köhler; Ed Hurt
Journal:  Mol Cell       Date:  2010-04-09       Impact factor: 17.970

3.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

Authors:  H A Coller; C Grandori; P Tamayo; T Colbert; E S Lander; R N Eisenman; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

4.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

5.  Cell cycle-dependent differences in nuclear pore complex assembly in metazoa.

Authors:  Christine M Doucet; Jessica A Talamas; Martin W Hetzer
Journal:  Cell       Date:  2010-06-11       Impact factor: 41.582

6.  A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.

Authors:  Duonan Yu; Andrei Thomas-Tikhonenko
Journal:  Oncogene       Date:  2002-03-14       Impact factor: 9.867

7.  Nuclear pores protect genome integrity by assembling a premitotic and Mad1-dependent anaphase inhibitor.

Authors:  Veronica Rodriguez-Bravo; John Maciejowski; Jennifer Corona; Håkon Kirkeby Buch; Philippe Collin; Masato T Kanemaki; Jagesh V Shah; Prasad V Jallepalli
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

8.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

Review 9.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

10.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

View more
  44 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  POM121 is a novel marker for predicting the prognosis of laryngeal cancer.

Authors:  Ruihua Zhao; Genxiong Tang; Tengqi Wang; Lingli Zhang; Wei Wang; Qiangfang Zhao; Kun Zhao
Journal:  Histol Histopathol       Date:  2020-10-05       Impact factor: 2.303

Review 3.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

4.  Scanning all chromosomal abnormalities with microarray-based comparative genomic hybridization in differential diagnosis of pediatric cancers.

Authors:  Hulya Tosun Yildirim; Safiye Aktas; Gulden Diniz; Tekincan Cagri Aktas; Burcin Baran; Serdar Bayrak; Zekiye Altun; Yasemin Cakir; Nur Olgun
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

5.  The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer.

Authors:  Cheng Zou; Dingxiao Zhang
Journal:  Mol Cell Oncol       Date:  2020-06-18

6.  Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.

Authors:  J Woo; S Santasusagna; J Banks; S Pastor-Lopez; K Yadav; M Carceles-Cordon; A Dominguez-Andres; R B Den; L R Languino; R Pippa; C D Lallas; G Lu-Yao; W K Kelly; K E Knudsen; V Rodriguez-Bravo; A K Tewari; J M Prats; B E Leiby; L G Gomella; Josep Domingo-Domenech
Journal:  J Urol       Date:  2020-04-06       Impact factor: 7.450

7.  Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth.

Authors:  Ekta Agarwal; Brian J Altman; Jae Ho Seo; Jagadish C Ghosh; Andrew V Kossenkov; Hsin-Yao Tang; Shiv Ram Krishn; Lucia R Languino; Dmitry I Gabrilovich; David W Speicher; Chi V Dang; Dario C Altieri
Journal:  J Biol Chem       Date:  2019-05-16       Impact factor: 5.157

8.  Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis.

Authors:  Ekta Agarwal; Brian J Altman; Jae Ho Seo; Irene Bertolini; Jagadish C Ghosh; Amanpreet Kaur; Andrew V Kossenkov; Lucia R Languino; Dmitry I Gabrilovich; David W Speicher; Chi V Dang; Dario C Altieri
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

Review 9.  Oncogenic potential of nucleoporins in non-hematological cancers: recent update beyond chromosome translocation and gene fusion.

Authors:  Adhiraj Roy; Gopeshwar Narayan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-25       Impact factor: 4.553

Review 10.  Cellular rewiring in lethal prostate cancer: the architect of drug resistance.

Authors:  Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2020-03-16       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.